Idience and Aptis collaborate to develop next-generation dual payload ADC cancer drug

CAR-T Digest - August 2020

12 August 2025: Idience and Aptis collaborate to develop next-generation dual payload ADC cancer drug

Idience and Aptis have signed a joint development agreement to create next-generation dual payload antibody-drug conjugate (ADC) cancer therapies
The collaboration will combine Idience’s PARP inhibitor drug Venadaparib with Aptis’s antibody-payload conjugation technology AbClick to enhance efficacy and safety
Dual payload ADCs deliver two different mechanisms of action via a single antibody, allowing for more precise and potent cancer cell targeting
This marks a strategic collaboration between Ildong Pharmaceutical Group and Dong-A Socio Group, aiming to advance innovation in oncology therapeutics
Both companies see the partnership as a breakthrough in expanding ADC applications and strengthening global competitiveness in cancer treatment development